Literature DB >> 23111763

Celiac disease: the new proposed ESPGHAN diagnostic criteria do work well in a selected population.

Gabriela Klapp1, Etna Masip, Miguel Bolonio, Ester Donat, Begoña Polo, David Ramos, Carmen Ribes-Koninckx.   

Abstract

BACKGROUND: The need for an early and accurate diagnosis in celiac disease (CD) has focused attention on new diagnostic approaches, based on the efficiency of serological markers and the high negative predictive value of human leukocyte antigen (HLA) non-DQ2/8.
METHODS: We performed a retrospective review of all of the patients suspected of having CD who had undergone a small bowel biopsy in our gastroenterology unit. All symptomatic children with serological marker at time of biopsy (immunoglobulin A-tissue transglutaminase antibody, endomysial antibody, and HLA genotype) were included. The triple test (TT) was positive if immunoglobulin A-tissue transglutaminase antibody was 10 times the upper limit of normal, plus positive endomysial antibody plus human leukocyte antigen-DQ2/DQ8.
RESULTS: A total of 150 patients met the inclusion criteria and were enrolled in the study. One hundred sixteen were positive for the TT; 113 of 116 (97.4%) had a Marsh 2/3 histological lesion and had been considered to have CD. Thus, positive predictive value of the TT was 97.4%. The other 3 cases (2.6%) had Marsh 0/1 lesion, so we consider them to be false-positives for the TT; however, on follow-up, all 3 children developed histological damage after a gluten challenge. Finally, the positive predictive value of the TT was 100%. Thirty-four patients were negative for the TT: 22 patients are celiac, 3 are celiac but challenge gluten diet is pending, and the 9 patients left have other gastrointestinal disorder.
CONCLUSIONS: Our study supports the view that in selected children who are symptomatic and positive for the TT, CD diagnosis could be established independent of histological findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23111763     DOI: 10.1097/MPG.0b013e318279887b

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  16 in total

1.  Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population.

Authors:  Dominica Gidrewicz; Kathryn Potter; Cynthia L Trevenen; Martha Lyon; J Decker Butzner
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

2.  Are ESPGHAN "biopsy-sparing" guidelines for celiac disease also suitable for asymptomatic patients?

Authors:  Chiara Maria Trovato; Monica Montuori; Caterina Anania; Maria Barbato; Anna Rita Vestri; Sofia Guida; Salvatore Oliva; Fabrizio Mainiero; Salvatore Cucchiara; Francesco Valitutti
Journal:  Am J Gastroenterol       Date:  2015-09-15       Impact factor: 10.864

3.  High-titre circulating tissue transglutaminase-2 antibodies predict small bowel villous atrophy, but decision cut-off limits must be locally validated.

Authors:  L Beltran; M Koenig; W Egner; M Howard; A Butt; M R Austin; D Patel; R R Sanderson; S Goubet; F Saleh; J Lavender; E Stainer; M D Tarzi
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

4.  Symptom positivity is essential for omitting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines.

Authors:  Jiri Nevoral; Radana Kotalova; Ondrej Hradsky; Vera Valtrova; Kristyna Zarubova; Jan Lastovicka; Eva Neubertova; Marketa Trnkova; Jiri Bronsky
Journal:  Eur J Pediatr       Date:  2013-11-15       Impact factor: 3.183

5.  ACG clinical guidelines: diagnosis and management of celiac disease.

Authors:  Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2013-04-23       Impact factor: 10.864

Review 6.  Intraepithelial lymphocytes, scores, mimickers and challenges in diagnosing gluten-sensitive enteropathy (celiac disease).

Authors:  Consolato Sergi; Fan Shen; Gerd Bouma
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

7.  Detection of specific IgA antibodies against a novel deamidated 8-Mer gliadin peptide in blood plasma samples from celiac patients.

Authors:  Sara Vallejo-Diez; David Bernardo; María de Lourdes Moreno; Alba Muñoz-Suano; Luis Fernández-Salazar; Carmen Calvo; Carolina Sousa; José A Garrote; Angel Cebolla; Eduardo Arranz
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

8.  Antibodies in the diagnosis of coeliac disease: a biopsy-controlled, international, multicentre study of 376 children with coeliac disease and 695 controls.

Authors:  Johannes Wolf; Dirk Hasenclever; David Petroff; Thomas Richter; Holm H Uhlig; Martin W Laaß; Almuthe Hauer; Martin Stern; Xavier Bossuyt; Jan de Laffolie; Gunter Flemming; Danilo Villalta; Wolfgang Schlumberger; Thomas Mothes
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

9.  Celiac disease in the Mediterranean area.

Authors:  Francesca Tucci; Luca Astarita; Abdelhak Abkari; Mona Abu-Zekry; Thomas Attard; Mongi Ben Hariz; José Ramon Bilbao; Ghazalia Boudraa; Samir Boukthir; Stefano Costa; Veselinka Djurisic; Jean-Pierre Hugot; Iñaki Irastorza; Aydan Kansu; Sanja Kolaček; Giuseppe Magazzù; Dušanka Mičetić-Turk; Zrinjka Misak; Eleftheria Roma; Pasqualino Rossi; Selma Terzic; Virtut Velmishi; Carmela Arcidiaco; Renata Auricchio; Luigi Greco
Journal:  BMC Gastroenterol       Date:  2014-02-11       Impact factor: 3.067

10.  Intraepithelial lymphocytes subsets in different forms of celiac disease.

Authors:  M Sánchez-Castañon; B G Castro; M Toca; C Santacruz; M Arias-Loste; P Iruzubieta; J Crespo; Marcos López-Hoyos
Journal:  Auto Immun Highlights       Date:  2016-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.